Literature DB >> 30705094

Differential effects of therapeutic complement inhibitors on serum bactericidal activity against non-groupable meningococcal isolates recovered from patients treated with eculizumab.

Dan M Granoff1, Howard Kim2, Nadav Topaz3, Jessica MacNeil3, Xin Wang3, Lucy A McNamara3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 30705094      PMCID： PMC6669166          DOI： 10.3324/haematol.2018.209692

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  15 in total

1.  Neisseria meningitidis group B correlates of protection and assay standardization--international meeting report Emory University, Atlanta, Georgia, United States, 16-17 March 2005.

Authors:  R Borrow; G M Carlone; N Rosenstein; M Blake; I Feavers; D Martin; W Zollinger; J Robbins; I Aaberge; D M Granoff; E Miller; B Plikaytis; L van Alphen; J Poolman; R Rappuoli; L Danzig; J Hackell; B Danve; M Caulfield; S Lambert; D Stephens
Journal:  Vaccine       Date:  2006-06-12       Impact factor: 3.641

2.  Complement-dependent synergistic bactericidal activity of antibodies against factor H-binding protein, a sparsely distributed meningococcal vaccine antigen.

Authors:  Jo Anne Welsch; Sanjay Ram; Oliver Koeberling; Dan M Granoff
Journal:  J Infect Dis       Date:  2008-04-01       Impact factor: 5.226

3.  Binding of complement factor H to PorB3 and NspA enhances resistance of Neisseria meningitidis to anti-factor H binding protein bactericidal activity.

Authors:  Serena Giuntini; Rolando Pajon; Sanjay Ram; Dan M Granoff
Journal:  Infect Immun       Date:  2015-02-02       Impact factor: 3.441

4.  Serum Bactericidal Antibody Responses of Adults Immunized with the MenB-4C Vaccine against Genetically Diverse Serogroup B Meningococci.

Authors:  Serena Giuntini; Eduardo Lujan; Malick M Gibani; Christina Dold; Christine S Rollier; Andrew J Pollard; Dan M Granoff
Journal:  Clin Vaccine Immunol       Date:  2017-01-05

5.  Meningococcal carriage among Georgia and Maryland high school students.

Authors:  Lee H Harrison; Kathleen A Shutt; Kathryn E Arnold; Eric J Stern; Tracy Pondo; Julia A Kiehlbauch; Robert A Myers; Rosemary A Hollick; Susanna Schmink; Marianne Vello; David S Stephens; Nancy E Messonnier; Leonard W Mayer; Thomas A Clark
Journal:  J Infect Dis       Date:  2014-12-11       Impact factor: 5.226

6.  Immunity to Neisseria meningitidis group B in adults despite lack of serum bactericidal antibody.

Authors:  Jo Anne Welsch; Dan Granoff
Journal:  Clin Vaccine Immunol       Date:  2007-10-03

Review 7.  Relative importance of complement-mediated bactericidal and opsonic activity for protection against meningococcal disease.

Authors:  Dan M Granoff
Journal:  Vaccine       Date:  2009-05-23       Impact factor: 3.641

8.  Use of Serogroup B Meningococcal Vaccines in Persons Aged ≥10 Years at Increased Risk for Serogroup B Meningococcal Disease: Recommendations of the Advisory Committee on Immunization Practices, 2015.

Authors:  Temitope Folaranmi; Lorry Rubin; Stacey W Martin; Manisha Patel; Jessica R MacNeil
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2015-06-12       Impact factor: 17.586

9.  Small-molecule factor D inhibitors selectively block the alternative pathway of complement in paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome.

Authors:  Xuan Yuan; Eleni Gavriilaki; Jane A Thanassi; Guangwei Yang; Andrea C Baines; Steven D Podos; Yongqing Huang; Mingjun Huang; Robert A Brodsky
Journal:  Haematologica       Date:  2016-11-03       Impact factor: 9.941

10.  Description and nomenclature of Neisseria meningitidis capsule locus.

Authors:  Odile B Harrison; Heike Claus; Ying Jiang; Julia S Bennett; Holly B Bratcher; Keith A Jolley; Craig Corton; Rory Care; Jan T Poolman; Wendell D Zollinger; Carl E Frasch; David S Stephens; Ian Feavers; Matthias Frosch; Julian Parkhill; Ulrich Vogel; Michael A Quail; Stephen D Bentley; Martin C J Maiden
Journal:  Emerg Infect Dis       Date:  2013-04       Impact factor: 6.883
View more
  4 in total

1.  Characteristics of and meningococcal disease prevention strategies for commercially insured persons receiving eculizumab in the United States.

Authors:  Catherine H Bozio; Cheryl Isenhour; Lucy A McNamara
Journal:  PLoS One       Date:  2020-11-12       Impact factor: 3.240

2.  Development and Optimization of Bifunctional Fusion Proteins to Locally Modulate Complement Activation in Diseased Tissue.

Authors:  Kelly C Fahnoe; Fei Liu; Jennifer G Morgan; Sarah T Ryan; Michael Storek; Ellen Garber Stark; Fred R Taylor; V Michael Holers; Joshua M Thurman; Stefan Wawersik; Susan L Kalled; Shelia M Violette
Journal:  Front Immunol       Date:  2022-06-16       Impact factor: 8.786

3.  Alternative Complement Pathway Inhibition Does Not Abrogate Meningococcal Killing by Serum of Vaccinated Individuals.

Authors:  Emma Ispasanie; Lukas Muri; Anna Schubart; Christine Thorburn; Natasa Zamurovic; Thomas Holbro; Michael Kammüller; Gerd Pluschke
Journal:  Front Immunol       Date:  2021-10-08       Impact factor: 7.561

4.  Danicopan: an oral complement factor D inhibitor for paroxysmal nocturnal hemoglobinuria

Authors:  Antonio M Risitano; Austin G Kulasekararaj; Jong Wook Lee; Jaroslaw P Maciejewski; Rosario Notaro; Robert Brodsky; Mingjun Huang; Michael Geffner; Peter Browett
Journal:  Haematologica       Date:  2021-12-01       Impact factor: 9.941
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.